Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

• Fotios Loupakis, Annamaria Ruzzo, +17 authors Francesco Graziano
• British Journal of Cancer
• 2009

Background:KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with… (More)

Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

• Fotios Loupakis, Chiara Cremolini, Gabriella Fontanini, Irene Stasi, Lisa Salvatore, Alfredo Falcone
• Therapeutic advances in medical oncology
• 2009

The monoclonal antibodies cetuximab and panitumumab, directed against the epidermal growth factor receptor (EGFR), are licensed for the treatment of KRAS wild-type metastatic colorectal cancer… (More)

E7A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors…

• Irene Stasi, Azzurra Farnesi, +15 authors Gabriella Fontanini
• 2017

Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment

• Fotios Loupakis, Irene Stasi, +12 authors Alfredo Falcone
• 2008

Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)

• Fotios Loupakis, Irene Stasi, +17 authors Alfredo Falcone
• 2008

Cetuximab plus irinotecan in irinotecan-resistant elderly metastatic coloretal cancer patients: clinical outcome according to KRAS and BRAF mutational status

• Gianluca Baldi, Lorenzo Fornaro, +12 authors Alfredo Falcone
• 2010

• ‹
• 1
• ›